Barclays
ETON icon

Barclays’s Eton Pharmaceutcials ETON Stock Holding History

Barclays’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Sell
49,374
-2,074
-4% -$36.3K ﹤0.01% 2631
2025
Q4 		$870K Buy
51,448
+14,642
+40% +$258K ﹤0.01% 3536
2025
Q3 		$800K Sell
36,806
-8,984
-20% -$149K ﹤0.01% 3507
2025
Q2 		$653K Buy
45,790
+1,129
+3% +$17.8K ﹤0.01% 3610
2025
Q1 		$580K Sell
44,661
-10,225
-19% -$154K ﹤0.01% 3438
2024
Q4 		$731K Buy
+54,886
New +$557K ﹤0.01% 3589
2021
Q4 		– Sell
-2,137
Closed -$11K – 4271
2021
Q3 		$11K Sell
2,137
-1,853
-46% -$9.64K ﹤0.01% 4500
2021
Q2 		$25K Sell
3,990
-10,288
-72% -$76.2K ﹤0.01% 4422
2021
Q1 		$104K Buy
14,278
+8,767
+159% +$74.8K ﹤0.01% 3984
2020
Q4 		$45K Sell
5,511
-1,209
-18% -$9.33K ﹤0.01% 4449
2020
Q3 		$53K Sell
6,720
-1,344
-17% -$9.18K ﹤0.01% 4569
2020
Q2 		$45K Buy
+8,064
New +$40K ﹤0.01% 4968
2019
Q2 		– Sell
-8,800
Closed -$70K – 7014
2019
Q1 		$70K Buy
+8,800
New +$61.1K ﹤0.01% 5637

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Barclays's ETON Position: Q1 2026 in Review

Barclays reduced its Eton Pharmaceutcials (ETON) stake by 4% in Q1 2026, selling an estimated $36.3K and leaving 49,374 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2631.

Barclays first reported a position in ETON in Q1 2019 and has held it in 13 quarters since. 116 funds tracked by Wall St. Rank hold ETON as of Q1 2026.

  • Barclays held 49,374 shares of Eton Pharmaceutcials worth $1.22M as of Q1 2026.
  • Barclays sold 2,074 Eton Pharmaceutcials shares in Q1 2026, an estimated $36.3K.
  • Eton Pharmaceutcials made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2631 holding.
  • Barclays first reported a position in Eton Pharmaceutcials in Q1 2019 and has held it in 13 quarters since.
  • 116 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.